Treatment Clinical Trial
— PEACOfficial title:
Protective Effect of Aspirin on COVID-19 Patients
Verified date | March 2020 |
Source | Xijing Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
COVID-19 has a high infection rate and mortality, and serious complications such as heart
injury cannot be ignored. Cardiac dysfunction occurred in COVID-19 patients, but the law and
mechanism of cardiac dysfunction remains unclear. The occurrence of progressive inflammatory
factor storm and coagulation dysfunction in severe and fatal cases of NCP points out a new
direction for reducing the incidence of severe and critically ill patients, shortening the
length of duration in severe and critically ill patients and reducing the incidence of
complications of cardiovascular diseases. Aspirin has the triple effects of inhibiting virus
replication, anticoagulant and anti-inflammatory, but it has not received attention in the
treatment and prevention of NCP. Although Aspirin is not commonly used in the guidelines for
the treatment of NCP, it was widely used in the treatment and prevention of a variety of
human diseases after its first synthesis in 1898. Subsequently, aspirin has been confirmed to
have antiviral effect on multiple levels. Moreover, one study has confirmed that aspirin can
inhibit virus replication by inhibiting prostaglandin E2 (PGE2) in macrophages and
upregulation of type I interferon production. Subsequently, pharmacological studies have
found that aspirin as an anti-inflammatory and analgesic drug by inhibiting cox-oxidase
(COX). Under certain conditions, the platelet is the main contributor of innate immune
response, studies have found that in the lung injury model in dynamic neutrophil and platelet
aggregation.
In summary, the early use of aspirin in covid-19 patients, which has the effects of
inhibiting virus replication, anti-platelet aggregation, anti-inflammatory and anti-lung
injury, is expected to reduce the incidence of severe and critical patients, shorten the
length of hospital duration and reduce the incidence of cardiovascular complications.
Status | Enrolling by invitation |
Enrollment | 128 |
Est. completion date | June 2020 |
Est. primary completion date | April 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: 1. The patient volunteered to participate in the study, approved the aspirin treatment, and was willing to randomly accept one of the aspirin treatment regimens, and provided written informed consent, 2. Subject is required to meet one of the following criteria for confirmation of a novel coronavirus infection with pneumonia: 1.The detection of novel coronavirus nucleic acid is positive in respiratory or blood specimens by Real-time -PCR, 2. Virus gene sequencing of respiratory or blood specimen is highly homologous with known novel coronavirus, 3. Chest image confirmed pulmonary involvement; 4. fever: =36.7? under the armpit, =38.0? in the oral cavity or =38.6? in the rectum and eardrum; • respiratory frequency =24 times/min or at least one cough; 5. Onset time =14 days; 6. Agree not to participate in another study until completion of the 14-day study; If you need to withdraw from this study; 7. The subjects had not taken aspirin for nearly one month prior to the screening period. 8. Can follow the study or follow up procedure. - Exclusion Criteria: 1. Women who have recently been pregnant or breast-feeding. 2. Having a history of active gastrointestinal bleeding in the past 3 months. 3. Blood routine examination showed that the platelet count was < 30×109/L. 4. Patients with coagulation disorders. 5. Unable to understand the potential risks and benefits of the study, and unable to follow up the evaluation as required. 6. Having no capacity for civil conduct. 7. A history of drug or alcohol abuse. 8. Allergic to aspirin. 9. Influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia, organized pneumonia, etc. 10. Patients with cardiac stent placement (< 1 year). 11. Any more complex medical problems that may interfere with research behavior or lead to increased risk, such as malignant tumors, blood diseases, liver diseases, AIDS, viral hepatitis, etc. |
Country | Name | City | State |
---|---|---|---|
China | Cai Yue | Xi'an | Shaanxi |
Lead Sponsor | Collaborator |
---|---|
Xijing Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | clinical recovery time (TTCR) | TTCR is defined as the study treatment (oral aspirin enteric-coated tablet) began to fever, breathing rate, blood oxygen saturation recovery, and cough relieving for at least 72 hours. | not more than 14 days | |
Primary | the time of SARS-CoV2 overcasting | Time of SARS-CoV2 in upper respiratory tract specimens overcasting detected by RT-PCR. | not more than 37 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05243134 -
The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation
|
||
Completed |
NCT02486874 -
Clinical Evaluation of PoreSkin
|
Phase 1 | |
Active, not recruiting |
NCT04592640 -
Stem Cells for Uremic Calciphylaxis Patients
|
N/A | |
Recruiting |
NCT04599686 -
Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer
|
N/A | |
Recruiting |
NCT03351842 -
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
|
Phase 2 | |
Completed |
NCT03439930 -
The Effect of Balance Training on Neuromuscular Control in Subjects With CAI
|
N/A | |
Completed |
NCT02782442 -
Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM)
|
N/A | |
Not yet recruiting |
NCT05537155 -
Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery
|
N/A | |
Recruiting |
NCT02971982 -
PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia
|
Phase 1/Phase 2 | |
Completed |
NCT02820272 -
Water for Reducing Pain in Negative Pressure Wound Therapy
|
Phase 2 | |
Completed |
NCT00984958 -
Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure
|
N/A | |
Completed |
NCT00575224 -
Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9
|
Phase 4 | |
Completed |
NCT00164528 -
Intervening With Children/Adolescents With FAS/ARND
|
Phase 1/Phase 2 | |
Completed |
NCT00164307 -
Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships
|
Phase 1/Phase 2 | |
Recruiting |
NCT04603586 -
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
|
N/A | |
Recruiting |
NCT03375424 -
Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany
|
N/A | |
Not yet recruiting |
NCT04062370 -
Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
|
Phase 4 | |
Not yet recruiting |
NCT02931136 -
Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
|
Phase 4 | |
Completed |
NCT04661228 -
Diagnostic Survey of Mental and Substance Use Disorders in HUNT (PsykHUNT)
|
||
Recruiting |
NCT03365141 -
Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo
|
N/A |